Wednesday 9 April 2025, 12pm BST
Hilco is seeking offers to acquire the intellectual property and tangible assets of Cryogatt Systems Limited (In Liquidation) (“Cryogatt” or the “Company”) on behalf of the Joint Liquidators of the Company, Laurence Pagden and Giuseppe Parla of Menzies LLP.
Founded in 2010, Cryogatt quickly established itself as a leading innovator in the specialised field of cryogenic RFID technology. The Company developed advanced solutions to address critical challenges associated with the secure storage, management, and traceability of biological specimens at temperatures as low as -196°C. Cryogatt’s proprietary technology enabled precise, reliable, and automated tracking of sensitive biological assets, such as embryos, gametes, cell therapies, and clinical samples, addressing the growing global demand for stringent sample identification and regulatory compliance.
Cryogatt’s suite of cryogenic RFID solutions encompassed patented RFID tagging methodologies specifically engineered for integration into cryogenic straws, vials, and storage bags. The Company’s proprietary hardware and software offer significant operational improvements over traditional manual or barcode-based systems, including high-speed bulk reading capabilities, accuracy under conditions of severe frost accumulation, automated audit processes, and adherence to rigorous international regulatory standards.
The Company’s innovations are underpinned by a robust intellectual property portfolio comprising multiple granted patents covering key RFID components, interrogation probes, and specialised tagging processes for extreme cryogenic environments. In addition to its patents, Cryogatt maintained extensive organisational knowledge and technical documentation, including detailed engineering schematics, software source codes, process algorithms, and comprehensive validation data amassed through over a decade of dedicated research, development, and global deployment.
Cryogatt successfully collaborated with internationally recognised institutions such as Public Health England’s Rare and Imported Pathogen Laboratory (Porton Down) and the National Institute for Biological Standards and Control (NIBSC), as well as numerous Assisted Reproductive Technology (ART) clinics worldwide. These strategic partnerships validated the reliability, efficacy, and regulatory compliance of Cryogatt’s technology, cementing the Company’s reputation as a trusted provider within highly regulated sectors. With established global distribution channels and strategic collaborations, including partnerships with Planer Ltd in Europe and InterMedics in Asia, Cryogatt showed significant commercial traction and the potential for rapid scaling into new international markets.
This acquisition opportunity provides investors with a pathway to leverage Cryogatt’s extensive intellectual property, including its patented RFID solutions, proprietary software, unique technical designs, and comprehensive data sets, offering considerable potential for further commercialisation in the rapidly growing fields of IVF, cell and gene therapy, biobanking, and beyond.
Established in 2010, Cryogatt has carved out a reputation as an innovator and global leader in cryogenic RFID technology. Over more than a decade, the Cryogatt brand has built a name synonymous with cutting-edge solutions for secure, reliable, and precise management of biological specimens in extreme conditions.
Cryogatt set itself apart by pioneering robust, cryo-resistant RFID tagging systems and proprietary software, significantly advancing sample management in assisted reproduction (IVF), biobanking, cell and gene therapies, and beyond. At the heart of its success are patented RFID methodologies specifically engineered to function flawlessly at ultra-low temperatures of -196°C, transforming industry expectations for accuracy and efficiency.
Strategic endorsements and investments have further enhanced the brand’s stature. Cryogatt received prestigious recognition through an Innovate UK grant, underscoring its critical contributions to biotechnology and life sciences sectors. Collaborative partnerships with internationally renowned institutions such as Public Health England and the National Institute for Biological Standards and Control (NIBSC) have cemented Cryogatt’s reputation for regulatory excellence, technological reliability, and industry-leading expertise.
Today, Cryogatt remains a recognised force in the rapidly growing cryogenic storage industry, driven by innovation, strategically supported by global partnerships, and trusted worldwide for safeguarding the integrity of invaluable biological assets.
The Company likely holds rights in unregistered trade marks protecting the “Cryogatt” brand name and logo.
Full details on the Company’s trade marks are available via a virtual data room.
The Cryogatt patent portfolio spans crucial innovations, including patented cryo-resistant RFID tags specifically designed for integration with cryogenic storage straws, vials, caps, and lids. These advancements are integral to automated identification, robust traceability, and real-time asset management of biologically sensitive samples at ultra-low temperatures. Further patents cover unique interrogation probes and RFID readers, reinforcing the Company’s expertise in remote, non-invasive tracking of critical biological materials.
Cryogatt’s patented solutions demonstrate clear innovation and distinct advantages in RFID-based cryogenic sample management, particularly in enabling precise, automated auditing of specimen identity and location, minimising manual handling, and enhancing compliance with stringent regulatory standards. The emphasis on wireless, secure identification and robust data management directly mirrors recent industry trends and innovations from major market players specialising in advanced cryogenic storage and tracking systems.
Specifically, Cryogatt’s patented RFID interrogation devices, RFID caps and lids, and advanced RFID readers equipped with specialised antenna arrays offer unparalleled precision and operational efficiency, positioning the technology to provide critical advantages in rapidly evolving sectors such as assisted reproduction, biobanking, and cellular therapies. Each patent signifies a pivotal technological milestone, driving precision, security, and efficiency in cryogenic sample management.
Full details on Cryogatt’s patents are available via a virtual data room.
For specific details on the patent portfolio acquisition opportunity, please find a short teaser here, with further details available upon request.
Cryogatt holds an extensive and meticulously maintained repository of organisational knowledge and know-how that underpins its proprietary cryogenic RFID solutions. This comprehensive portfolio includes detailed engineering designs, precise technical schematics, and proprietary software source code, all of which document over a decade of research, innovation, and rigorous real-world validation.
The repository features proprietary methodologies developed for the integration and optimisation of RFID technology in ultra-low temperature environments, specifically targeting the unique challenges associated with biological sample identification, auditing, and regulatory compliance. These methodologies are supported by extensive operational data and validation reports, offering deep insights into sample stability, read accuracy, and system reliability under cryogenic conditions.
Additionally, Cryogatt retains critical trial data and performance analytics demonstrating the scalability, precision, and operational effectiveness of its patented RFID tags, interrogation probes, and reader arrays. This robust technical foundation provides invaluable insights for future product development, enhancement, and commercial deployment within cryogenic storage sectors such as IVF clinics, biobanking facilities, and cellular therapy providers.
All essential documentation is securely stored within the Company’s centralised digital systems, encompassing critical intellectual property, regulatory compliance documentation, software archives, strategic business insights, and customer and distributor information. Collectively, this well-structured knowledge base equips potential acquirers with a comprehensive resource, enabling seamless integration and immediate commercial leverage of Cryogatt’s proven expertise and innovative methodologies into existing or emerging operations.
Cryogatt’s operations were underpinned by proprietary software solutions specifically developed to optimise the efficiency, accuracy, and regulatory compliance of cryogenic sample management. The Company designed and implemented tailored RFID software platforms, enabling precise real-time monitoring, seamless integration with cryogenic RFID hardware, and automated auditing processes. These software systems provided comprehensive sample tracking, reduced manual intervention, and ensured strict adherence to global regulatory standards.
The Company holds the primary cryogatt.com domain name, along with the cryogatt.co.uk and cryogatt.uk domain names.
The Company owns the copyright in the website content hosted at https://www.cryogatt.com/ and its additional domains, showcasing the business, its advanced cryogenic RFID technologies, and innovative solutions for biological specimen management.
Rights in social media accounts are also available to acquire across LinkedIn, and YouTube, Twitter, Facebook, Instagram and Pinterest.
Full details on the Company’s social media accounts are available via a virtual data room.
Stock may also be available to acquire.
The deadline for offers is extended to Wednesday 9 April 2025, 12pm BST
All expressions of interest and bids are to be directed to Hilco in writing. A Bid Submission Form is available on request. Please contact Hilco to gain access to a virtual data room of further information on signing a confidentiality agreement.
The Joint Liquidators acts as an agent of the Company and without personal liability.
The bidder acknowledges that Hilco acts as an agent for the Joint Liquidator who offers for sale only what right, title and interest (if any) the Company possesses in the assets. Such sale will be without any warranties, expressed or implied. The information provided has not been verified by Hilco or the Joint Liquidator, and bidders are deemed to have carried out their own due diligence.
VAT, if applicable, at 20% will be added to the price. A non-refundable deposit of 20% will be payable by the buyer within 48 hours of bid acceptance. A buyer’s premium of 10% of the sale price is payable by the winning bidder. Legal completion to occur within 5 business days of bid acceptance. Hilco’s full Terms and Conditions apply.
Associate Director
London Office
Associate Director
Manchester Office
